Gunther Wiesner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gunther Wiesner has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Peter Tassani
4 shared publicationsKlaus Martin
3 shared publicationsMichael Gruber
3 shared publications- Ralph Gertler
Klinik für Anaesthesie, operative und allgemeine Intensivmedizin, Notfallmedizin, Klinikum Links der Weser, University Medical Center Hamburg-Eppendorf, Bremen, Germany
3 shared publications Siegmund-Lorenz Braun
2 shared publications- Birgit Waschulzik
Institute for AI and Informatics in Medicine, Technical University of Munich School of Medicine, 81675 Munich, Germany
1 shared publication
Latest Publications
- Open Access
- 22 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (11) , 3619
Preoperative Hyperlactatemia Predicts Mortality in Acute Stanford Type A Dissection: A 16-Year-Period, Single-Center, Retrospective Study
Background: Acute Stanford Type A aortic dissection (ATAAD) is a devastating disease requiring immediate surgery. A life-threatening complication hereby represents organ malperfusion. Lactate is a product of anaerobic glycolysis indicating organ malperfusion. The current study analyzes preoperative lactate acidosis as a surrogate marker for patients’ outcome after surgery for ATAAD over a 15-year period. Methods: In a single-center setting, 306 consecutive patients, who underwent surgery for ATAAD between 2000 and 2016, were analyzed retrospectively. Serum lactate measurements were taken before surgery. To define a simple cut-point of the predictor lactate, the maximally selected rank statistics method was used. Results: Median survival was 9.3 ± 0.5 and CI 95% [8.3–10.2] years. Mean lactate levels were 1.95 mmol/L ± 2.19 mmol/L (range: 0.15–19.27 mmol/L). Patients with a lactate level > 3.71 mmol/L had a higher 30-day mortality compared to patients with lactate levels ≤ 3.71 mmol/L (51.5% versus 18.7%). In a logistic regression model adjusted for clinical baseline characteristics at index procedure, lactate levels > 3.71 mmol/L reached the highest Odd for 30-day mortality of all tested risk factors (OR = 7.292; CI95% [3.029–17.555]; p < 0.0001). Analyzing the overall mortality, the early effect of lactate level > 3.71 mmol/L persists. The HRs for overall mortality, however, revealed substantially lower effects (HR = 2.772; (CI95% [1.689–4.550]; p < 0.0001). In patients who survived the first 30 days postoperatively, no clinical parameter other than age had a significant impact on survival, including lactate > 3.71 mmol/L (p = 0.494). Conclusions: In patients with ATAAD, preoperative lactate represents an easily obtainable surrogate marker for organ malperfusion. A preoperative lactate level > 3.71 mmol/L depicts the strongest marker for early mortality after surgery.
- 22 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (11) , 3619
Open AccessPreoperative Hyperlactatemia Predicts Mortality in Acute Stanford Type A Dissection: A 16-Year-Period, Single-Center, Retrospective Study
Background: Acute Stanford Type A aortic dissection (ATAAD) is a devastating disease requiring immediate surgery. A life-threatening complication hereby represents organ malperfusion. Lactate is a product of anaerobic glycolysis indicating organ malperfusion. The current study analyzes preoperative lactate acidosis as a surrogate marker for patients’ outcome after surgery for ATAAD over a 15-year period. Methods: In a single-center setting, 306 consecutive patients, who underwent surgery for ATAAD between 2000 and 2016, were analyzed retrospectively. Serum lactate measurements were taken before surgery. To define a simple cut-point of the predictor lactate, the maximally selected rank statistics method was used. Results: Median survival was 9.3 ± 0.5 and CI 95% [8.3–10.2] years. Mean lactate levels were 1.95 mmol/L ± 2.19 mmol/L (range: 0.15–19.27 mmol/L). Patients with a lactate level > 3.71 mmol/L had a higher 30-day mortality compared to patients with lactate levels ≤ 3.71 mmol/L (51.5% versus 18.7%). In a logistic regression model adjusted for clinical baseline characteristics at index procedure, lactate levels > 3.71 mmol/L reached the highest Odd for 30-day mortality of all tested risk factors (OR = 7.292; CI95% [3.029–17.555]; p < 0.0001). Analyzing the overall mortality, the early effect of lactate level > 3.71 mmol/L persists. The HRs for overall mortality, however, revealed substantially lower effects (HR = 2.772; (CI95% [1.689–4.550]; p < 0.0001). In patients who survived the first 30 days postoperatively, no clinical parameter other than age had a significant impact on survival, including lactate > 3.71 mmol/L (p = 0.494). Conclusions: In patients with ATAAD, preoperative lactate represents an easily obtainable surrogate marker for organ malperfusion. A preoperative lactate level > 3.71 mmol/L depicts the strongest marker for early mortality after surgery.
- 4 November 2016
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 106 (2) , 160-161
Comment to: De Waha S, Seeburger J et al. (2016): Deep sedation versus general anaesthesia in percutaneous edge-to edge mitral valve reconstruction using the MitraClip system. Clin Res Cardiol 105(6):535–43
- 4 November 2016
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 106 (2) , 160-161
Comment to: De Waha S, Seeburger J et al. (2016): Deep sedation versus general anaesthesia in percutaneous edge-to edge mitral valve reconstruction using the MitraClip system. Clin Res Cardiol 105(6):535–43
- Open Access
- 18 January 2012
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 41 (2) , 466
Is tranexamic acid really an alternative to aprotinin?
In the April 2011 issue, Schindler et al. [1] presented tranexamic acid as an adequate alternative to aprotinin for antifibrinolytic therapy in pediatric congenital heart surgery. They compared postoperative blood loss and transfusion requirements between two periods of time – a former one with aprotinin and a later one with tranexamic acid – and noted no difference. This conclusion cannot be drawn from their results. The precondition for such study must be that the aprotinin and the tranexamic acid groups are comparable. This precondition is more than questionable because there are striking differences between the two groups: significant differences were observed in the preoperative coagulation values (Table 1), the time of aortic clamping and the amount of intraoperative platelets (Table 2), the postoperative fluid balance (Table 3) and the postoperative coagulation values (Table 4) [1]. For example, the higher preoperative laboratory values of fibrinogen and platelets favour the aprotinin group, whereas the higher amount of intraoperative platelets, the more negative postoperative fluid balance and the shorter postoperative PTT favour the tranexamic acid group. The authors themselves admit that there was a lower average mortality and an increase in the ‘surgical performance’ during the tranexamic acid period. This may simply explain why tranexamic acid was not inferior to aprotinin. The opposite is the case if the two periods of time are really comparable as we could demonstrate recently [2]. Due to the lack of prospective randomized controlled trials, currently retrospective cohort studies are needed to assess the effectiveness (and the side effects) of antifibrinolytic drugs in pediatric cardiac surgery. However, these retrospective cohort studies have to be well controlled which is not the case for the present study by Schindler et al. [1] Therefore, the question if tranexamic acid is a suitable substitute to aprotinin to reduce blood loss and transfusion requirements in pediatric cardiac surgery remains open. With regard to possible side effects [2–5], its off-label use should be limited to individual cases where the probable benefits outweigh the risks.
- 18 January 2012
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 41 (2) , 466
Open AccessIs tranexamic acid really an alternative to aprotinin?
In the April 2011 issue, Schindler et al. [1] presented tranexamic acid as an adequate alternative to aprotinin for antifibrinolytic therapy in pediatric congenital heart surgery. They compared postoperative blood loss and transfusion requirements between two periods of time – a former one with aprotinin and a later one with tranexamic acid – and noted no difference. This conclusion cannot be drawn from their results. The precondition for such study must be that the aprotinin and the tranexamic acid groups are comparable. This precondition is more than questionable because there are striking differences between the two groups: significant differences were observed in the preoperative coagulation values (Table 1), the time of aortic clamping and the amount of intraoperative platelets (Table 2), the postoperative fluid balance (Table 3) and the postoperative coagulation values (Table 4) [1]. For example, the higher preoperative laboratory values of fibrinogen and platelets favour the aprotinin group, whereas the higher amount of intraoperative platelets, the more negative postoperative fluid balance and the shorter postoperative PTT favour the tranexamic acid group. The authors themselves admit that there was a lower average mortality and an increase in the ‘surgical performance’ during the tranexamic acid period. This may simply explain why tranexamic acid was not inferior to aprotinin. The opposite is the case if the two periods of time are really comparable as we could demonstrate recently [2]. Due to the lack of prospective randomized controlled trials, currently retrospective cohort studies are needed to assess the effectiveness (and the side effects) of antifibrinolytic drugs in pediatric cardiac surgery. However, these retrospective cohort studies have to be well controlled which is not the case for the present study by Schindler et al. [1] Therefore, the question if tranexamic acid is a suitable substitute to aprotinin to reduce blood loss and transfusion requirements in pediatric cardiac surgery remains open. With regard to possible side effects [2–5], its off-label use should be limited to individual cases where the probable benefits outweigh the risks.
- Open Access
- 3 October 2011
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (1) , 230-233
Neither moxifloxacin nor cefuroxime produces significant attenuation of inflammatory mediator release in patients exposed to cardiopulmonary bypass: a randomized controlled trial
In vitro and experimental studies in animals have established the anti-inflammatory effects of moxifloxacin. Cardiopulmonary bypass (CPB) leads to an inflammatory response. The aim of this study was to assess whether the inflammatory cytokine response to CPB is reduced with a perioperative antibiotic prophylaxis, either moxifloxacin or cefuroxime (the standard prophylaxis). Twenty-eight patients scheduled for elective coronary artery bypass grafting with CPB were randomly assigned to receive either moxifloxacin or cefuroxime as the perioperative antibiotic prophylaxis. Interleukin (IL)-6, -8, -10 and tumour necrosis factor-α (TNF-α) serum concentrations were determined at eight time points before and after CPB. In both groups, all cytokine concentrations significantly increased after the start of CPB. There were no statistically significant differences between the moxifloxacin and cefuroxime groups at any point; IL-6 concentrations [median (interquartile range)] 240 min after CPB, the primary endpoint, were 364 (192–598) and 465 (325–906) pg/mL (P = 0.323), respectively. Neither moxifloxacin nor cefuroxime produced significant attenuation of the inflammatory cytokine response to CPB. The reasons why moxifloxacin did not have significant anti-inflammatory effects in this unique clinical situation may be: (i) the inflammatory response to CPB may be different from that of infectious disease states that were used to establish the immunomodulatory effects of moxifloxacin; and (ii) a single intravenous dose, which was used in this investigation, may not lead to high enough plasma and intracellular concentrations.
- 3 October 2011
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (1) , 230-233
Open AccessNeither moxifloxacin nor cefuroxime produces significant attenuation of inflammatory mediator release in patients exposed to cardiopulmonary bypass: a randomized controlled trial
In vitro and experimental studies in animals have established the anti-inflammatory effects of moxifloxacin. Cardiopulmonary bypass (CPB) leads to an inflammatory response. The aim of this study was to assess whether the inflammatory cytokine response to CPB is reduced with a perioperative antibiotic prophylaxis, either moxifloxacin or cefuroxime (the standard prophylaxis). Twenty-eight patients scheduled for elective coronary artery bypass grafting with CPB were randomly assigned to receive either moxifloxacin or cefuroxime as the perioperative antibiotic prophylaxis. Interleukin (IL)-6, -8, -10 and tumour necrosis factor-α (TNF-α) serum concentrations were determined at eight time points before and after CPB. In both groups, all cytokine concentrations significantly increased after the start of CPB. There were no statistically significant differences between the moxifloxacin and cefuroxime groups at any point; IL-6 concentrations [median (interquartile range)] 240 min after CPB, the primary endpoint, were 364 (192–598) and 465 (325–906) pg/mL (P = 0.323), respectively. Neither moxifloxacin nor cefuroxime produced significant attenuation of the inflammatory cytokine response to CPB. The reasons why moxifloxacin did not have significant anti-inflammatory effects in this unique clinical situation may be: (i) the inflammatory response to CPB may be different from that of infectious disease states that were used to establish the immunomodulatory effects of moxifloxacin; and (ii) a single intravenous dose, which was used in this investigation, may not lead to high enough plasma and intracellular concentrations.
- 1 June 2010
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 37 (6) , 1396-1401
Efficiency and safety of preoperative autologous blood donation in cardiac surgery: a matched-pair analysis in 432 patients
A shortage of blood products is predicted for the near future in many countries all over the world. Preoperative autologous blood donation (PABD) in cardiac surgery is considered an option to reduce the need of allogeneic blood products. We analysed a 1-year period of our institutional database according to the safety and efficiency of our autologous blood donation programme. All patients who donated autologous blood prior to cardiac surgery were matched to a non-donor according to age, body weight, body mass index, sex, haemoglobin concentration, EuroSCORE, antifibrinolytic therapy and risk for bleeding. We analysed the occurrence of adverse effects during donation in all donors as well as the main perioperative data, haemoglobin levels and the need for allogeneic blood transfusion in all patients. There were no major cardiac events such as myocardial infarction, worsened cardiac insufficiency or death in the donor group during the PABD process. A total of 216 patients could be matched. Exposure to allogeneic blood products was significantly reduced in the donor group (packed red cells 70 patients (pts) vs 118 pts (p<0.001), fresh frozen plasma 26 pts vs 54 pts (p=0.001), platelets 10 pts vs 22 pts (p=ns)). There were no reports of transfusion-related side effects. Further, there was no difference in haemoglobin concentrations at postoperative day 1 and at discharge. In this large matched-pair analysis without the need for risk stratification, PABD reduces the need for allogeneic blood products in adult cardiac surgery. In a carefully selected cohort, PABD is a safe and efficient alternative to allogeneic transfusion.
- 1 June 2010
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 37 (6) , 1396-1401
Efficiency and safety of preoperative autologous blood donation in cardiac surgery: a matched-pair analysis in 432 patients
A shortage of blood products is predicted for the near future in many countries all over the world. Preoperative autologous blood donation (PABD) in cardiac surgery is considered an option to reduce the need of allogeneic blood products. We analysed a 1-year period of our institutional database according to the safety and efficiency of our autologous blood donation programme. All patients who donated autologous blood prior to cardiac surgery were matched to a non-donor according to age, body weight, body mass index, sex, haemoglobin concentration, EuroSCORE, antifibrinolytic therapy and risk for bleeding. We analysed the occurrence of adverse effects during donation in all donors as well as the main perioperative data, haemoglobin levels and the need for allogeneic blood transfusion in all patients. There were no major cardiac events such as myocardial infarction, worsened cardiac insufficiency or death in the donor group during the PABD process. A total of 216 patients could be matched. Exposure to allogeneic blood products was significantly reduced in the donor group (packed red cells 70 patients (pts) vs 118 pts (p<0.001), fresh frozen plasma 26 pts vs 54 pts (p=0.001), platelets 10 pts vs 22 pts (p=ns)). There were no reports of transfusion-related side effects. Further, there was no difference in haemoglobin concentrations at postoperative day 1 and at discharge. In this large matched-pair analysis without the need for risk stratification, PABD reduces the need for allogeneic blood products in adult cardiac surgery. In a carefully selected cohort, PABD is a safe and efficient alternative to allogeneic transfusion.
- 9 July 2008
- Published by Wiley in Anaesthesia
- Vol. 63 (8) , 861-864
Increased formation of sister chromatid exchanges, but not of micronuclei, in anaesthetists exposed to low levels of sevoflurane
Summary: We have assessed, for the first time, genotoxicity (i.e. sister chromatid exchanges and micronuclei) in anaesthetists exposed to a single volatile anaesthetic (sevoflurane) without nitrous oxide. The anaesthetists were exposed to an 8‐h time‐weighted average of 0.2 parts per million sevoflurane. Internists served as non‐exposed controls. Mean (SD) sister chromatid exchanges per cell were significantly higher in anaesthetists compared to internists (6.6 (0.9) vs 5.1 (0.8); p < 0.001) whereas median (IQR [range]) micronuclei per 1000 binucleated cells did not differ (9.5 (6.3–10.8 [2.0–15.5]) vs 8.5 (6.0–10.5 [3.0–25.5]), respectively). Although the anaesthetists were exposed to rather low concentrations of sevoflurane, this 30% increase of sister chromatid exchanges is in agreement with a recently reported 300% increase with a high level exposure to sevoflurane and nitrous oxide. Omitting nitrous oxide does not normalise increased rates of sister chromatid exchanges.
- 9 July 2008
- Published by Wiley in Anaesthesia
- Vol. 63 (8) , 861-864
Increased formation of sister chromatid exchanges, but not of micronuclei, in anaesthetists exposed to low levels of sevoflurane
Summary: We have assessed, for the first time, genotoxicity (i.e. sister chromatid exchanges and micronuclei) in anaesthetists exposed to a single volatile anaesthetic (sevoflurane) without nitrous oxide. The anaesthetists were exposed to an 8‐h time‐weighted average of 0.2 parts per million sevoflurane. Internists served as non‐exposed controls. Mean (SD) sister chromatid exchanges per cell were significantly higher in anaesthetists compared to internists (6.6 (0.9) vs 5.1 (0.8); p < 0.001) whereas median (IQR [range]) micronuclei per 1000 binucleated cells did not differ (9.5 (6.3–10.8 [2.0–15.5]) vs 8.5 (6.0–10.5 [3.0–25.5]), respectively). Although the anaesthetists were exposed to rather low concentrations of sevoflurane, this 30% increase of sister chromatid exchanges is in agreement with a recently reported 300% increase with a high level exposure to sevoflurane and nitrous oxide. Omitting nitrous oxide does not normalise increased rates of sister chromatid exchanges.
- 1 February 2006
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 53 (2) , 208-209
Temperature, the benzoylcholine substrate, and fluoride inhibition of pseudocholinesterase
- 1 February 2006
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 53 (2) , 208-209
Temperature, the benzoylcholine substrate, and fluoride inhibition of pseudocholinesterase